Loading stock data…
ABT
$82.56-1.76 (-2.09%)
Market ClosedLast close May 11
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Abbott Laboratories in the Healthcare sector is trading at $82.56. The stock is currently near its 52-week low of $81.97, remaining 30.1% below its 200-day moving average. Technical signals show oversold RSI of 23 and bearish MACD signal, explaining why ABT maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 23) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$82.56
Potential Downside
9%
Whystock Fair Value$75.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Buy
Mean target$118.64+43.7%
Range$92.00 – $143.00
Fundamentals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$159.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.69
Beta
Defensive asset. Lower volatility than the S&P 500.
0.78
Div Yield
Strong income play. Yield provides a meaningful total return floor.
275.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.82%
Volume
Today's trading volume
16.24M
Recent News
A Look At Abbott Laboratories (ABT) Valuation After Mixed Q1 Results And Baby Formula Legal Ruling
Abbott Laboratories (ABT) is back in focus after mixed first quarter results, a cut to its 2026 adjusted EPS outlook tied to the Exact Sciences acquisition, and a large baby formula legal verdict that raised fresh questions. See our latest analysis for Abbott Laboratories. The recent mix of weaker first quarter sentiment, the Exact Sciences related EPS guidance cut and the baby formula verdict has coincided with a sharp reset in expectations. The share price is down 15.9% over 30 days and...
What This Fund’s $4 Million Apollo Commercial Real Estate Finance Sale Could Signal About CRE Risk
This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress
Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.
Abbott Laboratories: Mispriced Growth Behind Near-Term Noise?
The company combines strong device growth with an attractive valuation despite near-term headwinds.
Tandem Diabetes Care Q1 Earnings Call Highlights
Tandem Diabetes Care (NASDAQ:TNDM) reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product